Vipin Gopal

About Vipin Gopal

Vipin Gopal was appointed as a non-employee director of Concentra Group Holdings Parent, Inc. (CON) effective July 1, 2025, with his initial term set to expire at the 2026 Annual Meeting of Stockholders . He brings 25+ years of data, AI, and digital transformation leadership as Chief Data & Analytics Officer at Eli Lilly and Walgreens Boots Alliance, senior vice president of analytics at Humana, and prior roles at Cigna, United Technologies, and Honeywell; he holds a PhD from Carnegie Mellon, a B.Tech from IIT Bombay, and an MBA from NYU Stern . Upon appointment, the company stated no related-party transactions requiring disclosure and noted his eligibility for non-employee director compensation per CON’s proxy program .

Past Roles

Organization	Role	Tenure	Committees/Impact
Eli Lilly and Company	Chief Data & Analytics Officer	Not disclosed in CON filings	Led enterprise next-generation data/AI strategy and operations
Walgreens Boots Alliance	Chief Data & Analytics Officer	Not disclosed in CON filings	Led enterprise next-generation data/AI strategy and operations
Humana	Senior Vice President, Analytics	Not disclosed in CON filings	Enterprise analytics leadership across lines of business
Cigna; United Technologies; Honeywell	Leadership roles	Not disclosed in CON filings	Technology and analytics roles driving business value

External Roles

Organization	Capacity	Tenure	Notes
Carnegie Mellon University	PhD (Engineering)	—	Academic credential
IIT Bombay	B.Tech (Engineering)	—	Academic credential
NYU Stern School of Business	MBA	—	Academic credential

Board Governance

Appointment and term: appointed June 26, 2025 (effective July 1, 2025); term expires at the 2026 Annual Meeting; no arrangements with third parties; no related-party transactions under Item 404(a) disclosed at appointment .
Committee assignments: not disclosed in available filings as of November 19, 2025. CON is phasing committees to full independence under NYSE rules by November 2025 (Audit and Compliance Committee, Human Capital and Compensation Committee, Nominating, Governance and Sustainability Committee) .
Board leadership and structure: Chairman (Robert A. Ortenzio) and Lead Director (Daniel J. Thomas), with independent executive sessions led by the Lead Director; Board meets at least quarterly (held two meetings in FY2024; all then-current directors attended) .

Fixed Compensation

CON’s non-employee director compensation program (FY2024 structure, applicable to Gopal as a non-employee director):

Component	Amount/Terms
Quarterly cash retainer	$12,500 per quarter
Board meeting fees (in-person / telephonic)	$3,000 in-person; $600 telephonic
Audit & Compliance Committee fees	$3,000 in-person ($4,000 if independent of Board meeting); $1,500 telephonic; Chair receives $1,000 in-person or $500 telephonic per meeting
Quality of Care & Patient Safety Committee fees	$2,000 in-person ($3,000 if independent of Board meeting); $1,000 telephonic; Chair receives $1,000 in-person or $500 telephonic per meeting
All other committees fees	$1,000 in-person ($2,000 if independent of Board meeting); $500 telephonic
Stock ownership guideline (directors)	Minimum ownership equal to 5x annual cash compensation (excluding meeting fees); three years to comply

Performance Compensation

Annual equity compensation for non-employee directors (program-level; not specific to Gopal’s grant):

Metric	Value / Terms
Annual equity grant	12,992 restricted shares granted to each non-employee director on Nov 26, 2024
Vesting schedule	50% “onboarding grant” vests in equal annual tranches over five years; 50% “annual grant” vests after first anniversary
Performance conditions	None disclosed; time-based vesting only for directors

Other Directorships & Interlocks

CON’s appointment 8-K and press release detail executive roles but do not list other public company board service for Gopal; no related-party transactions with CON disclosed at appointment .

Expertise & Qualifications

Technical domain: enterprise data/AI strategy, advanced analytics, and digital transformation across payer, provider, pharma, and retail pharmacy sectors .
Education: PhD (Carnegie Mellon), B.Tech (IIT Bombay), MBA (NYU Stern) .

Equity Ownership

Item	Status / Amount
Initial beneficial ownership (Form 3)	No securities beneficially owned as of event date 07/01/2025; Form 3 filed 07/02/2025
Power of Attorney for Section 16 filings	Executed Limited Power of Attorney designating Timothy F. Ryan on 06/24/2025
Director stock ownership guideline	Must reach 5x annual cash compensation within three years of appointment
Anti-hedging policy	Prohibits directors and employees from hedging Concentra securities; adopted in 2024

Governance Assessment

Signals of independence and alignment: non-employee director status; no related-party transactions disclosed at appointment; subject to director stock ownership guidelines and company anti-hedging policy .
Transparency gaps: committee assignments, chair roles, and attendance for 2025 not yet disclosed; expect updates in the next proxy as CON completes NYSE phase-in to fully independent committees by November 2025 .
Compensation structure: cash retainers plus meeting/committee fees and time-vested equity grants; program-level detail available, but specific grants for Gopal not disclosed in current filings; initial Form 3 showed no holdings, typical for new appointees prior to grant issuance .
RED FLAGS: None disclosed for Gopal (no related-party transactions; no hedging permitted). Broader board-level transition risk exists as CON finalizes committee independence under NYSE rules by November 2025 .